![]()
-
教授
- 电子邮箱:921c3ac54d21006e3c5838e39b14d7a8172e50ce415756bdd2858f1270976cbad066e3c1a464649f5bad9dc86d35eeda506bca6f1e9c7e66a35180dff505f4f39d7d6407afbbe04a0c5642557ef951f3ab36edd7fefd2b2a1e43f5eacdaa55241abdb00abb294a2d724cafa27be701701f8a3f7898a052e04dfa12bc51a89de5
- 学位:博士
访问量:
-
[ 1 ]5. Liu Y, Qian P, Chen C, Lu X, Sun B, Zhang X, Wang L, Gao X, Li H, Chen Z, Tang J, Zhang W, Dong J, Bai R, Lobie PE, Wu Q, Liu S, Zhang H, Zhao F, Wicha MS, Zhu T*, Zhao Y*. (2015) Gd-metallofullerenol nanomaterial nanomaterial as non-toxic cancer stem cell specific inhibitor. Nat Commun. 6,5988..2021,
-
[ 2 ]4. Li G, Wu X, Qian W, Wu ZS, Cai H, Sun X, Zhang W, Tan S, Qian P, Ding K, Lu X, Zhang X, Yan H, Song H, Huang S, Wu Q, Lobie PE, Shan G, Zhu T (2016) CCAR1 5'UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance. Cell Res 26:655-73..2021,
-
[ 3 ]3. Tan S, Li H, Zhang W, Shao Y, Liu Y, Guan H, WU J, Kang Y, Zhao J, Yu Q, Gu Y, Ding K, Zhang M, Qian W, Zhu Y, Cai H, Chen C, Lobie PE, Zhao X*, Sun J* Zhu T* (2018) NUDT21 Negatively Regulates PSMB2 and CXXC5 by Alternative Polyadenylation and Contributes to Hepatocellular Carcinoma Suppression. Oncogene 37(35):4887-4900.2021,
-
[ 4 ]2. Zhang W, Wu M, Kang Y, Chong QY, Zhang M, Qian W, Zhang X, Hu L, Zhong Y, Qian P, Kong X, Li G, Ding K, Lobie PE*, Zhu T* (2018)Loss of Estrogen Regulated MIR135A1 at 3p21.1 Promotes Tamoxifen Resistance in Breast Cancer Cells. Cancer Res. 78(17):4915-4928.2021,
-
[ 5 ]1. Lu X, Zhu Y, Bai R, Wu Z, Qian W, Yang L, Pandey V, Liu Y, Lobie PE, Chen C*, Zhu T*. (2019) Long-term pulmonary pre-exposure to multi-walled carbon nanotubes promotes breast cancer metastatic cascades. Nature Nanotechnol. 14(7):719-727.2021,
-
[ 6 ]朱涛.Artemin is hypoxia responsive and promotes oncogenicity and increased
tumor initiating capacity in hepatocellular carcinoma.ONCOTARGET,2016,7(3):3257-3272.
-
[ 1 ]Oc001载体及Oc002,Oc003,Oc004,Oc005蛋白质功能的深入研究,进行,
-
[ 2 ]Oc001载体及Oc002,Oc003,Oc004,Oc005蛋白质功能的初步研究,进行,
-
[ 3 ]雌激素调控的LncRNA-ERLC1介导的信号网络在乳腺癌内分泌治疗中的功能与机制研究,进行,
-
[ 4 ]hsa-let-7g对乳腺癌细胞转移和浸润能力的抑制及分子机制的初步探讨,完成,
-
[ 5 ]lncRNA参与抗肿瘤治疗改造微环境的作用与机制及其影响治疗反应性的研究,进行,
-
[ 6 ]TP53INP1 5UTR与SIRT1 5UTR协同调控乳腺肿瘤细胞化疗抗性的研究,进行,